Genprex Inc’s (NASDAQ:GNPX) chairman and chief executive, Rodney Varner has trumpeted the gene therapy company’s recent achievements, noting that it has completed part of its overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex immunogene therapy, to commercialization.
In a statement on Tuesday, Varner said: “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initiatives.”
He added: “These accomplishments have set the stage for us to continue on our path of growth and expansion, enabling our efforts to bring our drug candidate to market for lung cancer patients who cannot benefit from today’s therapies.”
The recent achievements are outlined in the company’s newly launched, interactive corporate timeline, which can be found on Genprex’s website.
Contact the author at [email protected]